NIIMBL is collaborating with member organizations to develop and launch an open-access Adeno-associated viral (AAV) vector platform to lower the technical hurdles in the development of novel gene therapies. A team of expert scientists is working collaboratively to furnish a suite of therapeutic-agnostic process and analytical protocols that will be publicly available to support the development and manufacture of novel AAV-based therapies.
We are seeking community input to ensure this platform meets the needs of sponsors engaged in drug development for rare genetic disorders. Specifically, we want to hear from patient organizations, academic researchers, and small companies embarked on the journey of drug development.
To gather this feedback, NIIMBL has contracted Radius Insights to conduct a Voice of Customer analysis via compensated virtual interviews.
If you or your organization has been, or is currently, engaged in developing an AAV gene therapy for a rare indication, your feedback would be immensely helpful!
Please indicate your interest by completing the form by November 17, 2025.
Additionally, if you know others who may be interested in participating in an interview, please feel free to forward this opportunity to your colleagues.
For more information, please contact NIIMBL Viral Vector Program Lead, Chris Williams, at [email protected].
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.
